<DOC>
	<DOCNO>NCT00837265</DOCNO>
	<brief_summary>Determination effect Neugranin duration severity severe neutropenia .</brief_summary>
	<brief_title>Neugranin Breast Cancer Patients Receiving Doxorubicin/Docetaxel</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Breast cancer patient schedule receive AT regimen ( doxorubicin/ docetaxel ) . Subjects may receive 1 prior chemotherapy regimen ( include adjuvant therapy give within last 12 month ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Breast Cancer Supportive Care Neutropenia</keyword>
</DOC>